Revisión sistemática sobre la identificación de factores predictores de la adicción a opioides

El uso de opioides ha estado incrementado durante los últimos años, al igual que las tasas de adicción por trastornos por consumo de opioides (TCO) y sobredosis a causa de estos; es por esto que se busca identificar aquellos factores predictores de la adicción a opioides al igual que las escalas que...

Full description

Autores:: Cardona Restrepo, Mariajose

Tipo de recurso:: https://purl.org/coar/resource_type/c_7a1f

Fecha de publicación:: 2024

Institución:: Universidad El Bosque

Repositorio:: Repositorio U. El Bosque

Idioma:: spa

id	UNBOSQUE2_bab384948aaf1ff05041cdadfa6fccef
oai_identifier_str	oai:repositorio.unbosque.edu.co:20.500.12495/12121
network_acronym_str	UNBOSQUE2
network_name_str	Repositorio U. El Bosque
repository_id_str
dc.title.none.fl_str_mv	Revisión sistemática sobre la identificación de factores predictores de la adicción a opioides
dc.title.translated.none.fl_str_mv	Systematic review on identifying predictors of opioid addiction
title	Revisión sistemática sobre la identificación de factores predictores de la adicción a opioides
spellingShingle	Revisión sistemática sobre la identificación de factores predictores de la adicción a opioides Adicción a opioides Factores de riesgo Escalas 615.19 Opioid addiction Risk factors Scores
title_short	Revisión sistemática sobre la identificación de factores predictores de la adicción a opioides
title_full	Revisión sistemática sobre la identificación de factores predictores de la adicción a opioides
title_fullStr	Revisión sistemática sobre la identificación de factores predictores de la adicción a opioides
title_full_unstemmed	Revisión sistemática sobre la identificación de factores predictores de la adicción a opioides
title_sort	Revisión sistemática sobre la identificación de factores predictores de la adicción a opioides
dc.creator.fl_str_mv	Cardona Restrepo, Mariajose
dc.contributor.advisor.none.fl_str_mv	Castillo Suarez, Germán David Amaya Méndez, Sergio
dc.contributor.author.none.fl_str_mv	Cardona Restrepo, Mariajose
dc.subject.none.fl_str_mv	Adicción a opioides Factores de riesgo Escalas
topic	Adicción a opioides Factores de riesgo Escalas 615.19 Opioid addiction Risk factors Scores
dc.subject.ddc.none.fl_str_mv	615.19
dc.subject.keywords.none.fl_str_mv	Opioid addiction Risk factors Scores
description	El uso de opioides ha estado incrementado durante los últimos años, al igual que las tasas de adicción por trastornos por consumo de opioides (TCO) y sobredosis a causa de estos; es por esto que se busca identificar aquellos factores predictores de la adicción a opioides al igual que las escalas que permiten medir este riesgo. Métodos: Se realizó una revisión sistemática en las bases de datos Elsevier, Scopus y PubMed para hacer la recopilación de información cualitativa y cuantitativa (odds ratio) que permitiera reconocer los factores y su grado de incidencia. Resultados: Se identificó que los factores psiquiátricos corresponden a los factores más incidentes frente al TCO, al igual que el consumo previo de sustancias, principalmente opioides, presentar diagnósticos previos especialmente relacionados con patologías de alto dolor como el cáncer, y el uso de opioides postquirúrgico. Conclusiones: Se identificó que el factor de riesgo con mayor prevalencia es la presencia de enfermedades psiquiátricas, como la depresión, pero también se destacan factores como el uso concomitante de sustancias o diagnóstico de cáncer, los cuales aumentan el riesgo de generar TCO. Igualmente, se destacan las escalas COMM y SOAPP-R para la medición de este riego por su alta sensibilidad y efectividad.
publishDate	2024
dc.date.accessioned.none.fl_str_mv	2024-05-15T18:51:34Z
dc.date.available.none.fl_str_mv	2024-05-15T18:51:34Z
dc.date.issued.none.fl_str_mv	2024-04
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.local.none.fl_str_mv	Tesis/Trabajo de grado - Monografía - Pregrado
dc.type.coar.none.fl_str_mv	https://purl.org/coar/resource_type/c_7a1f
dc.type.driver.none.fl_str_mv	info:eu-repo/semantics/bachelorThesis
dc.type.coarversion.none.fl_str_mv	https://purl.org/coar/version/c_ab4af688f83e57aa
format	https://purl.org/coar/resource_type/c_7a1f
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/20.500.12495/12121
dc.identifier.instname.spa.fl_str_mv	Universidad El Bosque
dc.identifier.reponame.spa.fl_str_mv	reponame:Repositorio Institucional Universidad El Bosque
dc.identifier.repourl.none.fl_str_mv	repourl:https://repositorio.unbosque.edu.co
url	https://hdl.handle.net/20.500.12495/12121
identifier_str_mv	Universidad El Bosque reponame:Repositorio Institucional Universidad El Bosque repourl:https://repositorio.unbosque.edu.co
dc.language.iso.fl_str_mv	spa
language	spa
dc.relation.references.none.fl_str_mv	[1] WHO, “Opioid overdose,” 2022, no. August 2021, pp. 4–9, Accessed: Mar. 20, 2024. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/opioid-overdose. [2] L. R. Webster, “Risk Factors for Opioid-Use Disorder and Overdose,” Anesth. Analg., vol. 125, no. 5, pp. 1741–1748, 2017, doi: 10.1213/ANE.0000000000002496. [3] A. B. GALLEGOS GONZALES and H. D. C. MATTA NEGRI, “ROL DEL QUÍMICO FARMACÉUTICO EN EL DESARROLLO DE LA FARMACOVIGILANCIA POST-VACUNA COVID-19 EN ESTABLECIMIENTOS FARMACÉUTICOS,” Univ. Nac. “SAN LUIS GONZAGA” ICA, p. 105, 2021. [4] Ministerio de Justicia y del Derecho-Observatorio de Drogas de Colombia, “Alerta informativa acerca del uso de sustancias y preparados con actividad psicoactiva utilizadas para el manejo del dolor (opioides),” Sist. Alerta Tempranas, vol. 2019, pp. 1–8, 2019, [Online]. Available: https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis%0Ahttps://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis%0Ahttps://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis%0Ahttp://www.odc.gov.co/Portals/1/SAT/Alerta. [5] Oficina de las Naciones Unidas contra la droga y el delito., “Informe Mundial de Drogas 2018: crisis de opioides, abuso de medicamentos y niveles récord de opio y cocaína. Resumen, conclusiones y consecuencias en materia de políticas.” pp. 1–11, 2018, Accessed: Mar. 20, 2024. [Online]. Available: https://www.unodc.org/colombia/es/informe-mundial-de-drogas-2018_-crisis-de-opioides--abuso-de-medicamentos-y-niveles-record-de-opio-y-cocaina.html. [6] Ministerio de Justicia y el Derecho, “Estudio nacional de consumo de sustancias psicoactivas en Colombia. Informe final,” Ocd, p. 149, 2019, [Online]. Available: https://www.minjusticia.gov.co/programas-co/ODC/Documents/Publicaciones/Consumo/Estudios/estudio Nacional de consumo 2019v2.pdf?csf=1&e=iV5lh3. [7] D. P. BETANCOURT, “Resolucion 1478 De 2006,” Minist. LA PROTECCIÓN Soc., pp. 1–43, 2006, [Online]. Available: https://www.invima.gov.co/images/pdf/medicamentos/resoluciones/resolucion 001478 de 2006.pdf. [8] G. Brenner and C. Stevens, Brenner and Stevens’ Pharmacology, 5th Editio. Elsevier, 2018. [9] Alcohol and Drug Policy Commission, “Alcohol and Drug Policy Commission : Opiates or Opioids — What’s the difference? : State of Oregon,” oregon.gov, 2022. https://www.oregon.gov/adpc/pages/opiate-opioid.aspx (accessed Mar. 20, 2024). [10] G. Rang, H.P., Ritter, J.M., Flower, R.J., Henderson, Rang and Dale’s pharmacology, 10th Editi. 2007. [11] S. Wen, J. Muñoz, M. Mancilla, T. Bornhardt, A. Riveros, and V. Iturriaga, “Mecanismos de Modulación Central del Dolor: Revisión de la Literatura Mechanisms of Central Pain Modulation: Literature Review,” Int. J. Morphol, vol. 38, no. 6, pp. 1803–1809, 2020. [12] J. Listos, M. Łupina, S. Talarek, A. Mazur, J. Orzelska-Górka, and J. Kotlińska, “The mechanisms involved in morphine addiction: An overview,” International Journal of Molecular Sciences, vol. 20, no. 17. 2019, doi: 10.3390/ijms20174302. [13] National Institute on Drug abuse (NIDA), “Drug Misuse and Addiction \| National Institute on Drug Abuse (NIDA),” National Intitude on Drug Abuse. 2020, Accessed: Apr. 01, 2024. [Online]. Available: https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drug-misuse-addiction. [14] T. R. Kosten and T. P. George, “RESEARCH REVIEWS-THE NEUROBIOLOGY OF OPIOID DEPENDENCE • 1 3 The Neurobiology of Opioid Dependence: Implications for Treatment,” Sci Pr. Perspect, vol. 1, pp. 13–20, 2002. [15] F. P. Pastor and A. Sánchez, “USO Y MAL USO DE LOS FÁRMACOS OPIOIDES PARA EL TRATAMIENTO DEL DOLOR,” vol. 19, no. 1, pp. 31–35, 2019. [16] M. Gupta, S. B. Gokarakonda, and F. N. Attia, “Withdrawal Syndromes,” StatPearls, Apr. 2023, Accessed: Mar. 20, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK459239/. [17] B. Oprita, B. Aignatoaie, and D. A. Gabor-Postole, “Scores and scales used in emergency medicine. Practicability in toxicology,” J. Med. Life, vol. 7, no. Spec Iss 3, p. 4, 2014, Accessed: Mar. 20, 2024. [Online]. Available: /pmc/articles/PMC4391401/. [18] A. M. Dydyk, N. K. Jain, and M. Gupta, “Opioid Use Disorder,” StatPearls, Jan. 2024, Accessed: Mar. 26, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK553166/. [19] A. S. Tilhou et al., “Association between spine injury and opioid misuse in a prospective cohort of Level I trauma patients,” OTA Int. Open Access J. Orthop. Trauma, vol. 5, no. 3, p. e205, 2022, doi: 10.1097/oi9.0000000000000205. [20] A. A. Butt, P. Yan, S. Kapadia, A. B. Abou-Samra, N. Z. Janjua, and S. Ibrahim, “Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use,” Sci. Rep., vol. 11, no. 1, pp. 1–9, 2021, doi: 10.1038/s41598-021-85283-6. [21] L. Li, Y. Chang, S. Song, E. Losina, K. H. Costenbader, and T. M. Laidlaw, “Impact of reported NSAID ‘allergies’ on opioid use disorder in back pain,” J. Allergy Clin. Immunol., vol. 147, no. 4, pp. 1413–1419, 2021, doi: 10.1016/j.jaci.2020.08.025. [22] N. E. Onyeakusi et al., “Cancer-Related Pain Is an Independent Predictor of In-Hospital Opioid Overdose: A Propensity-Matched Analysis,” Pain Med. (United States), vol. 20, no. 12, pp. 2552–2561, 2019, doi: 10.1093/pm/pnz130. [23] J. M. Junge, H. Murray, A. H. Goldman, G. J. Booth, and G. C. Balazs, “Oral opioid prescribing to active duty US military personnel: a cross-sectional population,” Reg. Anesth. Pain Med., p. rapm-2023-104495, 2023, doi: 10.1136/rapm-2023-104495. [24] I. M. Meier et al., “Factors associated with use of opioid rescue medication after surgery,” Reg. Anesth. Pain Med., pp. 1–7, 2023, doi: 10.1136/rapm-2023-104412. [25] M. S. Baliss, M. Bilal, M. S. Abougergi, S. Umar, A. R. Shah, and P. Guturu, “Su1419 – One Year Risk of Opioid Addiction After an Episode of Acute Pancreatitis and Its Impact on Mortality and Healthcare Resource Utilization,” Gastroenterology, vol. 156, no. 6, p. S-540-S-541, 2019, doi: 10.1016/s0016-5085(19)38247-2. [26] P. Bruguera, P. Barrio, L. Ortega, A. I. Lopez-Lazcano, A. Fauli, and A. Lligoña, “Heavy prescription over time leading to opioid dependence,” J. Subst. Use, vol. 23, no. 6, pp. 579–583, 2018, doi: 10.1080/14659891.2018.1459903. [27] J. M. Just, L. Bingener, M. Bleckwenn, R. Schnakenberg, and K. Weckbecker, “Risk of opioid misuse in chronic non-cancer pain in primary care patients - A cross sectional study,” BMC Fam. Pract., vol. 19, no. 1, pp. 1–5, 2018, doi: 10.1186/s12875-018-0775-9. [28] S. Yennurajalingam et al., “Predicting the risk for aberrant opioid use behavior in patients receiving outpatient supportive care consultation at a comprehensive cancer center,” Cancer, vol. 124, no. 19, pp. 3942–3949, 2018, doi: 10.1002/cncr.31670. [29] L. K. Dunn et al., “Incidence and risk factors for chronic postoperative opioid use after major spine surgery: A cross-sectional study with longitudinal outcome,” Anesth. Analg., vol. 127, no. 1, pp. 247–254, 2018, doi: 10.1213/ANE.0000000000003338. [30] K. Namiranian, J. Siglin, J. D. Sorkin, E. J. Norris, M. Aghevli, and E. C. Covington, “Postoperative opioid misuse in patients with opioid use disorders maintained on opioid agonist treatment,” J. Subst. Abuse Treat., vol. 109, no. January 2019, pp. 8–13, 2020, doi: 10.1016/j.jsat.2019.10.007. [31] K. Ward, A. Ramzan, J. Sheeder, S. Fischer, and C. Lefkowits, “Persistent opioid use after radiation therapy in opioid-naive cervical cancer survivors,” Int. J. Gynecol. Cancer, vol. 29, no. 7, pp. 1105–1109, 2019, doi: 10.1136/ijgc-2019-000430. [32] L. K. Vitzthum et al., “Predicting Persistent Opioid Use, Abuse, and Toxicity among Cancer Survivors,” J. Natl. Cancer Inst., vol. 112, no. 7, pp. 720–727, 2020, doi: 10.1093/jnci/djz200. [33] S. C. Wilson, J. A. Shaffer, and A. B. Wachholtz, “Distress Tolerance in the Comorbid Chronic Pain and Opioid Use Disorder Population,” J. Addict. Med., vol. 17, no. 3, pp. E164–E171, 2023, doi: 10.1097/ADM.0000000000001106. [34] A. S. Bennett, J. A. Watford, L. Elliott, B. Wolfson-Stofko, and H. Guarino, “Military veterans’ overdose risk behavior: Demographic and biopsychosocial influences,” Addict. Behav., vol. 99, no. June, 2019, doi: 10.1016/j.addbeh.2019.106036. [35] C. P. Lobo et al., “Associations between the Specialty of Opioid Prescribers and Opioid Addiction, Misuse, and Overdose Outcomes,” Pain Med. (United States), vol. 21, no. 9, pp. 1871–1890, 2020, doi: 10.1093/PM/PNZ234. [36] National Institutes and H. and an educational grant from E. Pharmaceuticals, “Current Opioid Misuse Measure ( COMM ) TM,” Heal. (San Fr., 2008. [37] A. D. Nicholson, H. F. Kassam, J. Steele, N. Passarelli, T. A. Blaine, and D. Kovacevic, “* Development and Validation of a Risk Calculator for Prolonged Opioid Use After Shoulder Surgery,” J. Shoulder Elb. Surg., vol. 28, no. 8, pp. e288–e289, 2019, doi: 10.1016/j.jse.2019.04.033. [38] D. M. Simon, M. B. Peratikos, A. R. Watson, J. Shen, and E. A. Stringer, “Identifying individuals at risk for a future opioid use disorder diagnosis with machine learning,” Postgrad. Med., vol. 130, pp. 15–16, 2018, [Online]. Available: https://www.embase.com/search/results?subaction=viewrecord&id=L623800011&from=export%0Ahttp://dx.doi.org/10.1080/00325481.2018.1512253. [39] A. B. Anderson, C. F. Grazal, G. C. Balazs, B. K. Potter, J. F. Dickens, and J. A. Forsberg, “Can Predictive Modeling Tools Identify Patients at High Risk of Prolonged Opioid Use after ACL Reconstruction?,” Clin. Orthop. Relat. Res., vol. 478, no. 7, pp. 00–1618, 2020, doi: 10.1097/CORR.0000000000001251. [40] M. R. Clark, R. W. Hurley, and M. C. B. Adams, “Re-assessing the Validity of the Opioid Risk Tool in a Tertiary Academic Pain Management Center Population,” Pain Med. (United States), vol. 19, no. 7, pp. 1382–1395, 2018, doi: 10.1093/pm/pnx332. [41] A. V. Karhade, M. A. Chaudhary, C. M. Bono, J. D. Kang, J. H. Schwab, and A. J. Schoenfeld, “Validating the Stopping Opioids after Surgery (SOS) score for sustained postoperative prescription opioid use in spine surgical patients,” Spine J., vol. 19, no. 10, pp. 1666–1671, 2019, doi: 10.1016/j.spinee.2019.05.001. [42] M. Wong, A. Vogell, K. Wright, K. Isaacson, M. Loring, and S. Morris, “Opioid use after laparoscopic hysterectomy: prescriptions, patient use, and a predictive calculator,” Am. J. Obstet. Gynecol., vol. 220, no. 3, pp. 259.e1-259.e11, 2019, doi: 10.1016/j.ajog.2018.10.022. [43] S. R. Galindo et al., “Cross-cultural adaptation of the Pain Medication Questionnaire for use in Brazil,” BMC Med. Res. Methodol., vol. 19, no. 1, 2019, doi: 10.1186/s12874-019-0821-x. [44] J. M. Reps, M. Soledad Cepeda, and P. B. Ryan, “Wisdom of the Croud: Development and validation of a patient-level prediction model for opioid use disorder using population-level claims data,” PLoS One, vol. 15, no. 2, pp. 1–12, 2020, doi: 10.1371/journal.pone.0228632. [45] D. Molina and Á.-M. Miguel, “Estado de la investigación clínica en Colombia State of the clinical research in Colombia,” Acta Médica Colomb., vol. 43, no. 4, pp. 179–182, 2018. [46] R. Pérez Águila, J. L. Montes de Oca Montano, and A. Home Martínez, “Indización biomédica: sus tesauros, bases de datos y representación del contenido temático de la bibliografía especializada,” Bibl. Univ., vol. 26, no. 1, pp. 35–46, 2023, doi: 10.22201/dgbsdi.0187750xp.2023.1.1483. [47] Y. Kim et al., “Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: a Cohort Study,” J. Gen. Intern. Med., vol. 35, no. 9, pp. 2545–2552, 2020, doi: 10.1007/s11606-020-06001-y. [48] E. Kinnaird, A. Kimergård, S. Jennings, C. Drummond, and P. Deluca, “From pain treatment to opioid dependence: A qualitative study of the environmental influence on codeine use in UK adults,” BMJ Open, vol. 9, no. 4, pp. 1–10, 2019, doi: 10.1136/bmjopen-2018-025331. [49] C. Barbosa-Leiker, A. N. C. Campbell, R. K. McHugh, C. Guille, and S. F. Greenfield, “Opioid Use Disorder in Women and the Implications for Treatment,” Psychiatr. Res. Clin. Pract., vol. 3, no. 1, pp. 3–11, 2021, doi: 10.1176/appi.prcp.20190051. [50] S. A. Dominguez-Lara, “El odds ratio y su interpretación como magnitud del efecto en investigación,” Educ. Médica, vol. 19, no. 1, pp. 64–65, Jan. 2018, doi: 10.1016/j.edumed.2017.01.008. [51] J. D. Jones, S. Mogali, and S. D. Comer, “Polydrug abuse: A review of opioid and benzodiazepine combination use,” Drug Alcohol Depend., vol. 125, no. 1–2, pp. 8–18, 2012, doi: 10.1016/j.drugalcdep.2012.07.004. [52] M. Jani, B. B. Yimer, T. Sheppard, M. Lunt, and W. G. Dixon, “Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study,” PLoS Med., vol. 17, no. 10, pp. 1–16, 2020, doi: 10.1371/journal.pmed.1003270. [53] H. Samples, E. A. Stuart, and M. Olfson, “Opioid Use and Misuse and Suicidal Behaviors in a Nationally Representative Sample of US Adults,” Am. J. Epidemiol., vol. 188, no. 7, pp. 1245–1253, 2019, doi: 10.1093/aje/kwz061. [54] J. Lutz, R. T. Gross, and A. M. Vargovich, “Difficulties in emotion regulation and chronic pain-related disability and opioid misuse,” Addict. Behav., vol. 87, no. July, pp. 200–205, 2018, doi: 10.1016/j.addbeh.2018.07.018. [55] D. Reyes Chiquete, J. C. González Ortiz, A. Mohar Betancourt, and A. Meneses García, “Epidemiologíadel dolor por cáncer,” Rev. la Soc. Esp. del Dolor, vol. 18, no. 2, pp. 118–134, 2011. [56] K. Levytska et al., “Opioid and benzodiazepine use in gynecologic oncology patients,” Int. J. Gynecol. Cancer, vol. 33, no. 5, pp. 786–791, 2023, doi: 10.1136/ijgc-2022-003955. [57] N. Hernández-Beltrán, S. Forero-Nieto, and C. Moreno B, “Distal sensory peripheral neuropathy by the human immunodeficiency virus (HIV): pathophysiology,” Acta Neurológica Colomb., vol. 29, no. 2, pp. 103–108, 2013, [Online]. Available: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-87482013000200006&lng=en&nrm=iso&tlng=es. [58] V. J. Madden, R. Parker, and B. R. Goodin, “Chronic pain in people with HIV: A common comorbidity and threat to quality of life,” Pain Manag., vol. 10, no. 4, pp. 253–260, 2020, doi: 10.2217/pmt-2020-0004. [59] J. Colasanti et al., “Chronic Opioid Therapy in People Living with Human Immunodeficiency Virus: Patients’ Perspectives on Risks, Monitoring, and Guidelines,” Clin. Infect. Dis., vol. 68, no. 2, pp. 291–297, 2019, doi: 10.1093/cid/ciy452. [60] A. S. Ospina, D. M. Benjumea G, and P. Amariles M, “Problemas de proceso y resultado relacionados con los medicamentos: evolución histórica de sus definiciones,” Rev. Fac. Nac. Salud Pública, vol. 29, no. 3, pp. 329–340, 2011, [Online]. Available: http://www.scielo.org.co/pdf/rfnsp/v29n3/v29n3a14.pdf. [61] M. J. Krimphove* et al., “Pd58-03 Opioid Prescriptions After Robotic Vs. Open Urologic Procedures,” J. Urol., vol. 201, no. Supplement 4, p. 2019, 2019, doi: 10.1097/01.ju.0000557171.89602.04. [62] P. Sayal, B. T. Bateman, M. Menendez, M. Eikermann, and K. S. Ladha, “Opioid use disorders and the risk of postoperative pulmonary complications,” Anesth. Analg., vol. 127, no. 3, pp. 767–774, 2018, doi: 10.1213/ANE.0000000000003307. [63] N. Mendoza-Elias, M. Dunbar, Z. Ghogawala, and R. G. Whitmore, “Opioid Use, Risk Factors, and Outcome in Lumbar Fusion Surgery,” World Neurosurg., vol. 135, pp. e580–e587, 2020, doi: 10.1016/j.wneu.2019.12.073. [64] A. A. Anoushiravani et al., “Risk factors associated with persistent chronic opioid use following THA,” Eur. J. Orthop. Surg. Traumatol., vol. 30, no. 4, pp. 681–688, 2020, doi: 10.1007/s00590-019-02618-w. [65] M. K. Dalton et al., “Long-term prescription opioid use among US military service members injured in combat,” J. Trauma Acute Care Surg., vol. 91, no. 2, pp. S213–S220, 2021, doi: 10.1097/TA.0000000000003133. [66] L. Lundgren, M. Padyab, M. Sandlund, and D. McCarty, “Frequency and recency of non-medical opioid use and death due to overdose or suicide among individuals assessed for risky substance use: A national registry study in Sweden,” J. Subst. Abuse Treat., vol. 134, no. December 2020, p. 108567, 2022, doi: 10.1016/j.jsat.2021.108567. [67] E. L. Garland, M. Trostheim, M. Eikemo, G. Ernst, and S. Leknes, “Anhedonia in chronic pain and prescription opioid misuse,” Psychol. Med., vol. 50, no. 12, pp. 1977–1988, 2020, doi: 10.1017/S0033291719002010. [68] National Institutes and H. and an educational grant from E. Pharmaceuticals, “Screener and Opioid Assessment for Patients with Pain- Revised (SOAPP®-R),” pp. 1–4, 2015. [69] TUTFG, “Preguntas PICO: ¿Qué son y cómo se formulan?” https://tutfg.es/preguntas-pico/ (accessed Apr. 03, 2024). [70] V. Hernández, “Estudios epidemiológicos: tipos, diseño e interpretación,” Enferm. Inflamatoria Intest. al Día, vol. 16, no. 3, pp. 98–105, 2017, doi: 10.1016/j.eii.2017.03.001. [71] Elsevier, “Elsevier at a glance Because informed decisions lead to better outcomes,” 2022, [Online]. Available: https://www.elsevier.com/about/this-is-elsevier. [72] PubMed Central, “PMC User Guide - PMC,” 2023. https://www.ncbi.nlm.nih.gov/pmc/about/userguide/ (accessed Apr. 03, 2024). [73] Elsevier, “Scopus \| Abstract and citation database \| Elsevier,” Scopus: Comprehensive, multidisciplinary, trusted abstract and citation database, 2024. https://www.elsevier.com/products/scopus (accessed Apr. 03, 2024). [74] M. J. Ajejas Bazán, “Glosario de descriptores en Ciencias de la Salud procedentes del tesauro DeCS y MESH.,” Univ. Complut. Madrid, 2017. [75] NCBI, “Introduction to MeSH,” Medical Subject Headings, 2019. https://www.nlm.nih.gov/mesh/introduction.html (accessed Apr. 03, 2024). [76] B. V. em S. Bireme, “DeCS - Descriptores en ciencias de la salud,” 2008. https://decs.bvsalud.org/es/ (accessed Apr. 03, 2024). [77] C. Manterola, P. Astudillo, E. Arias, and N. Claros, “Revisiones sistemáticas de la literatura. Qué se debe saber acerca de ellas,” Cir. Esp., vol. 91, no. 3, pp. 149–155, 2013, doi: 10.1016/j.ciresp.2011.07.009. [78] J. M. Fernández, “Valoración clínica del paciente antes de iniciar el tratamiento con opioides : herramientas de ayuda .,” pp. 1–45.
dc.rights.en.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.uri.none.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.local.spa.fl_str_mv	Acceso abierto
dc.rights.accessrights.none.fl_str_mv	info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ Acceso abierto http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.none.fl_str_mv	application/pdf
dc.publisher.program.spa.fl_str_mv	Química Farmacéutica
dc.publisher.grantor.spa.fl_str_mv	Universidad El Bosque
dc.publisher.faculty.spa.fl_str_mv	Facultad de Ciencias
institution	Universidad El Bosque
bitstream.url.fl_str_mv	https://repositorio.unbosque.edu.co/bitstreams/16ca20e6-59e5-41e7-be5b-9f57620e1857/download https://repositorio.unbosque.edu.co/bitstreams/0e88cb0d-d1e5-45e4-b034-e3b11e794a45/download https://repositorio.unbosque.edu.co/bitstreams/b369a64d-670f-47ff-9a72-bcdd8f1079b3/download https://repositorio.unbosque.edu.co/bitstreams/1bd5b7b4-c426-4e23-a3d6-ce20975524e3/download https://repositorio.unbosque.edu.co/bitstreams/6e0e9d8a-166f-4131-980f-c2906515cde5/download https://repositorio.unbosque.edu.co/bitstreams/0d8cb2de-b288-4ccd-a421-c7148da31faf/download https://repositorio.unbosque.edu.co/bitstreams/4cb80a00-7464-48cf-ac02-6b6d88645e40/download
bitstream.checksum.fl_str_mv	17cc15b951e7cc6b3728a574117320f9 3ca9a52a4c8b51a2fa450031d1489211 e540e37387fb9f86b6af1d6f1f3125fc 3b6ce8e9e36c89875e8cf39962fe8920 3d807bb18e90285d84bbfe46d257e8ad 5727c19fafcbe6b0ea907e6cd99c0caa 640f51954e3eee21e860ae1470fcf953
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Institucional Universidad El Bosque
repository.mail.fl_str_mv	bibliotecas@biteca.com
_version_	1808397412911284224
spelling	Castillo Suarez, Germán DavidAmaya Méndez, SergioCardona Restrepo, Mariajose2024-05-15T18:51:34Z2024-05-15T18:51:34Z2024-04https://hdl.handle.net/20.500.12495/12121Universidad El Bosquereponame:Repositorio Institucional Universidad El Bosquerepourl:https://repositorio.unbosque.edu.coEl uso de opioides ha estado incrementado durante los últimos años, al igual que las tasas de adicción por trastornos por consumo de opioides (TCO) y sobredosis a causa de estos; es por esto que se busca identificar aquellos factores predictores de la adicción a opioides al igual que las escalas que permiten medir este riesgo. Métodos: Se realizó una revisión sistemática en las bases de datos Elsevier, Scopus y PubMed para hacer la recopilación de información cualitativa y cuantitativa (odds ratio) que permitiera reconocer los factores y su grado de incidencia. Resultados: Se identificó que los factores psiquiátricos corresponden a los factores más incidentes frente al TCO, al igual que el consumo previo de sustancias, principalmente opioides, presentar diagnósticos previos especialmente relacionados con patologías de alto dolor como el cáncer, y el uso de opioides postquirúrgico. Conclusiones: Se identificó que el factor de riesgo con mayor prevalencia es la presencia de enfermedades psiquiátricas, como la depresión, pero también se destacan factores como el uso concomitante de sustancias o diagnóstico de cáncer, los cuales aumentan el riesgo de generar TCO. Igualmente, se destacan las escalas COMM y SOAPP-R para la medición de este riego por su alta sensibilidad y efectividad.PregradoQuímico FarmacéuticoThe use of opioids has been increasing in recent years, as have the rates of opioid use disorder (OUD) addiction and opioid overdose; therefore, we sought to identify predictors of opioid addiction as well as scales to measure this risk. Methods: A systematic review was carried out in the Elsevier, Scopus and PubMed databases to compile qualitative and quantitative information (odds ratio) that would allow us to recognize the factors and their degree of incidence. Results: It was identified that psychiatric factors correspond to the most incident factors against OCT, as well as previous consumption of substances, mainly opioids, presenting previous diagnoses especially related to high pain pathologies such as cancer, and the use of opioids post-surgery. Conclusions: It was identified that the risk factor with the highest prevalence is the presence of psychiatric diseases, such as depression, but factors such as concomitant substance use or cancer diagnosis also stand out, which increase the risk of generating OCT. Likewise, the COMM and SOAPP-R scales stand out for the measurement of this risk due to their high sensitivity and effectiveness.application/pdfAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Acceso abiertoinfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Adicción a opioidesFactores de riesgoEscalas615.19Opioid addictionRisk factorsScoresRevisión sistemática sobre la identificación de factores predictores de la adicción a opioidesSystematic review on identifying predictors of opioid addictionQuímica FarmacéuticaUniversidad El BosqueFacultad de CienciasTesis/Trabajo de grado - Monografía - Pregradohttps://purl.org/coar/resource_type/c_7a1fhttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesishttps://purl.org/coar/version/c_ab4af688f83e57aa[1] WHO, “Opioid overdose,” 2022, no. August 2021, pp. 4–9, Accessed: Mar. 20, 2024. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/opioid-overdose.[2] L. R. Webster, “Risk Factors for Opioid-Use Disorder and Overdose,” Anesth. Analg., vol. 125, no. 5, pp. 1741–1748, 2017, doi: 10.1213/ANE.0000000000002496.[3] A. B. GALLEGOS GONZALES and H. D. C. MATTA NEGRI, “ROL DEL QUÍMICO FARMACÉUTICO EN EL DESARROLLO DE LA FARMACOVIGILANCIA POST-VACUNA COVID-19 EN ESTABLECIMIENTOS FARMACÉUTICOS,” Univ. Nac. “SAN LUIS GONZAGA” ICA, p. 105, 2021.[4] Ministerio de Justicia y del Derecho-Observatorio de Drogas de Colombia, “Alerta informativa acerca del uso de sustancias y preparados con actividad psicoactiva utilizadas para el manejo del dolor (opioides),” Sist. Alerta Tempranas, vol. 2019, pp. 1–8, 2019, [Online]. Available: https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis%0Ahttps://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis%0Ahttps://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis%0Ahttp://www.odc.gov.co/Portals/1/SAT/Alerta.[5] Oficina de las Naciones Unidas contra la droga y el delito., “Informe Mundial de Drogas 2018: crisis de opioides, abuso de medicamentos y niveles récord de opio y cocaína. Resumen, conclusiones y consecuencias en materia de políticas.” pp. 1–11, 2018, Accessed: Mar. 20, 2024. [Online]. Available: https://www.unodc.org/colombia/es/informe-mundial-de-drogas-2018_-crisis-de-opioides--abuso-de-medicamentos-y-niveles-record-de-opio-y-cocaina.html.[6] Ministerio de Justicia y el Derecho, “Estudio nacional de consumo de sustancias psicoactivas en Colombia. Informe final,” Ocd, p. 149, 2019, [Online]. Available: https://www.minjusticia.gov.co/programas-co/ODC/Documents/Publicaciones/Consumo/Estudios/estudio Nacional de consumo 2019v2.pdf?csf=1&e=iV5lh3.[7] D. P. BETANCOURT, “Resolucion 1478 De 2006,” Minist. LA PROTECCIÓN Soc., pp. 1–43, 2006, [Online]. Available: https://www.invima.gov.co/images/pdf/medicamentos/resoluciones/resolucion 001478 de 2006.pdf.[8] G. Brenner and C. Stevens, Brenner and Stevens’ Pharmacology, 5th Editio. Elsevier, 2018.[9] Alcohol and Drug Policy Commission, “Alcohol and Drug Policy Commission : Opiates or Opioids — What’s the difference? : State of Oregon,” oregon.gov, 2022. https://www.oregon.gov/adpc/pages/opiate-opioid.aspx (accessed Mar. 20, 2024).[10] G. Rang, H.P., Ritter, J.M., Flower, R.J., Henderson, Rang and Dale’s pharmacology, 10th Editi. 2007.[11] S. Wen, J. Muñoz, M. Mancilla, T. Bornhardt, A. Riveros, and V. Iturriaga, “Mecanismos de Modulación Central del Dolor: Revisión de la Literatura Mechanisms of Central Pain Modulation: Literature Review,” Int. J. Morphol, vol. 38, no. 6, pp. 1803–1809, 2020.[12] J. Listos, M. Łupina, S. Talarek, A. Mazur, J. Orzelska-Górka, and J. Kotlińska, “The mechanisms involved in morphine addiction: An overview,” International Journal of Molecular Sciences, vol. 20, no. 17. 2019, doi: 10.3390/ijms20174302.[13] National Institute on Drug abuse (NIDA), “Drug Misuse and Addiction \| National Institute on Drug Abuse (NIDA),” National Intitude on Drug Abuse. 2020, Accessed: Apr. 01, 2024. [Online]. Available: https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drug-misuse-addiction.[14] T. R. Kosten and T. P. George, “RESEARCH REVIEWS-THE NEUROBIOLOGY OF OPIOID DEPENDENCE • 1 3 The Neurobiology of Opioid Dependence: Implications for Treatment,” Sci Pr. Perspect, vol. 1, pp. 13–20, 2002.[15] F. P. Pastor and A. Sánchez, “USO Y MAL USO DE LOS FÁRMACOS OPIOIDES PARA EL TRATAMIENTO DEL DOLOR,” vol. 19, no. 1, pp. 31–35, 2019.[16] M. Gupta, S. B. Gokarakonda, and F. N. Attia, “Withdrawal Syndromes,” StatPearls, Apr. 2023, Accessed: Mar. 20, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK459239/.[17] B. Oprita, B. Aignatoaie, and D. A. Gabor-Postole, “Scores and scales used in emergency medicine. Practicability in toxicology,” J. Med. Life, vol. 7, no. Spec Iss 3, p. 4, 2014, Accessed: Mar. 20, 2024. [Online]. Available: /pmc/articles/PMC4391401/.[18] A. M. Dydyk, N. K. Jain, and M. Gupta, “Opioid Use Disorder,” StatPearls, Jan. 2024, Accessed: Mar. 26, 2024. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK553166/.[19] A. S. Tilhou et al., “Association between spine injury and opioid misuse in a prospective cohort of Level I trauma patients,” OTA Int. Open Access J. Orthop. Trauma, vol. 5, no. 3, p. e205, 2022, doi: 10.1097/oi9.0000000000000205.[20] A. A. Butt, P. Yan, S. Kapadia, A. B. Abou-Samra, N. Z. Janjua, and S. Ibrahim, “Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use,” Sci. Rep., vol. 11, no. 1, pp. 1–9, 2021, doi: 10.1038/s41598-021-85283-6.[21] L. Li, Y. Chang, S. Song, E. Losina, K. H. Costenbader, and T. M. Laidlaw, “Impact of reported NSAID ‘allergies’ on opioid use disorder in back pain,” J. Allergy Clin. Immunol., vol. 147, no. 4, pp. 1413–1419, 2021, doi: 10.1016/j.jaci.2020.08.025.[22] N. E. Onyeakusi et al., “Cancer-Related Pain Is an Independent Predictor of In-Hospital Opioid Overdose: A Propensity-Matched Analysis,” Pain Med. (United States), vol. 20, no. 12, pp. 2552–2561, 2019, doi: 10.1093/pm/pnz130.[23] J. M. Junge, H. Murray, A. H. Goldman, G. J. Booth, and G. C. Balazs, “Oral opioid prescribing to active duty US military personnel: a cross-sectional population,” Reg. Anesth. Pain Med., p. rapm-2023-104495, 2023, doi: 10.1136/rapm-2023-104495.[24] I. M. Meier et al., “Factors associated with use of opioid rescue medication after surgery,” Reg. Anesth. Pain Med., pp. 1–7, 2023, doi: 10.1136/rapm-2023-104412.[25] M. S. Baliss, M. Bilal, M. S. Abougergi, S. Umar, A. R. Shah, and P. Guturu, “Su1419 – One Year Risk of Opioid Addiction After an Episode of Acute Pancreatitis and Its Impact on Mortality and Healthcare Resource Utilization,” Gastroenterology, vol. 156, no. 6, p. S-540-S-541, 2019, doi: 10.1016/s0016-5085(19)38247-2.[26] P. Bruguera, P. Barrio, L. Ortega, A. I. Lopez-Lazcano, A. Fauli, and A. Lligoña, “Heavy prescription over time leading to opioid dependence,” J. Subst. Use, vol. 23, no. 6, pp. 579–583, 2018, doi: 10.1080/14659891.2018.1459903.[27] J. M. Just, L. Bingener, M. Bleckwenn, R. Schnakenberg, and K. Weckbecker, “Risk of opioid misuse in chronic non-cancer pain in primary care patients - A cross sectional study,” BMC Fam. Pract., vol. 19, no. 1, pp. 1–5, 2018, doi: 10.1186/s12875-018-0775-9.[28] S. Yennurajalingam et al., “Predicting the risk for aberrant opioid use behavior in patients receiving outpatient supportive care consultation at a comprehensive cancer center,” Cancer, vol. 124, no. 19, pp. 3942–3949, 2018, doi: 10.1002/cncr.31670.[29] L. K. Dunn et al., “Incidence and risk factors for chronic postoperative opioid use after major spine surgery: A cross-sectional study with longitudinal outcome,” Anesth. Analg., vol. 127, no. 1, pp. 247–254, 2018, doi: 10.1213/ANE.0000000000003338.[30] K. Namiranian, J. Siglin, J. D. Sorkin, E. J. Norris, M. Aghevli, and E. C. Covington, “Postoperative opioid misuse in patients with opioid use disorders maintained on opioid agonist treatment,” J. Subst. Abuse Treat., vol. 109, no. January 2019, pp. 8–13, 2020, doi: 10.1016/j.jsat.2019.10.007.[31] K. Ward, A. Ramzan, J. Sheeder, S. Fischer, and C. Lefkowits, “Persistent opioid use after radiation therapy in opioid-naive cervical cancer survivors,” Int. J. Gynecol. Cancer, vol. 29, no. 7, pp. 1105–1109, 2019, doi: 10.1136/ijgc-2019-000430.[32] L. K. Vitzthum et al., “Predicting Persistent Opioid Use, Abuse, and Toxicity among Cancer Survivors,” J. Natl. Cancer Inst., vol. 112, no. 7, pp. 720–727, 2020, doi: 10.1093/jnci/djz200.[33] S. C. Wilson, J. A. Shaffer, and A. B. Wachholtz, “Distress Tolerance in the Comorbid Chronic Pain and Opioid Use Disorder Population,” J. Addict. Med., vol. 17, no. 3, pp. E164–E171, 2023, doi: 10.1097/ADM.0000000000001106.[34] A. S. Bennett, J. A. Watford, L. Elliott, B. Wolfson-Stofko, and H. Guarino, “Military veterans’ overdose risk behavior: Demographic and biopsychosocial influences,” Addict. Behav., vol. 99, no. June, 2019, doi: 10.1016/j.addbeh.2019.106036.[35] C. P. Lobo et al., “Associations between the Specialty of Opioid Prescribers and Opioid Addiction, Misuse, and Overdose Outcomes,” Pain Med. (United States), vol. 21, no. 9, pp. 1871–1890, 2020, doi: 10.1093/PM/PNZ234.[36] National Institutes and H. and an educational grant from E. Pharmaceuticals, “Current Opioid Misuse Measure ( COMM ) TM,” Heal. (San Fr., 2008.[37] A. D. Nicholson, H. F. Kassam, J. Steele, N. Passarelli, T. A. Blaine, and D. Kovacevic, “* Development and Validation of a Risk Calculator for Prolonged Opioid Use After Shoulder Surgery,” J. Shoulder Elb. Surg., vol. 28, no. 8, pp. e288–e289, 2019, doi: 10.1016/j.jse.2019.04.033.[38] D. M. Simon, M. B. Peratikos, A. R. Watson, J. Shen, and E. A. Stringer, “Identifying individuals at risk for a future opioid use disorder diagnosis with machine learning,” Postgrad. Med., vol. 130, pp. 15–16, 2018, [Online]. Available: https://www.embase.com/search/results?subaction=viewrecord&id=L623800011&from=export%0Ahttp://dx.doi.org/10.1080/00325481.2018.1512253.[39] A. B. Anderson, C. F. Grazal, G. C. Balazs, B. K. Potter, J. F. Dickens, and J. A. Forsberg, “Can Predictive Modeling Tools Identify Patients at High Risk of Prolonged Opioid Use after ACL Reconstruction?,” Clin. Orthop. Relat. Res., vol. 478, no. 7, pp. 00–1618, 2020, doi: 10.1097/CORR.0000000000001251.[40] M. R. Clark, R. W. Hurley, and M. C. B. Adams, “Re-assessing the Validity of the Opioid Risk Tool in a Tertiary Academic Pain Management Center Population,” Pain Med. (United States), vol. 19, no. 7, pp. 1382–1395, 2018, doi: 10.1093/pm/pnx332.[41] A. V. Karhade, M. A. Chaudhary, C. M. Bono, J. D. Kang, J. H. Schwab, and A. J. Schoenfeld, “Validating the Stopping Opioids after Surgery (SOS) score for sustained postoperative prescription opioid use in spine surgical patients,” Spine J., vol. 19, no. 10, pp. 1666–1671, 2019, doi: 10.1016/j.spinee.2019.05.001.[42] M. Wong, A. Vogell, K. Wright, K. Isaacson, M. Loring, and S. Morris, “Opioid use after laparoscopic hysterectomy: prescriptions, patient use, and a predictive calculator,” Am. J. Obstet. Gynecol., vol. 220, no. 3, pp. 259.e1-259.e11, 2019, doi: 10.1016/j.ajog.2018.10.022.[43] S. R. Galindo et al., “Cross-cultural adaptation of the Pain Medication Questionnaire for use in Brazil,” BMC Med. Res. Methodol., vol. 19, no. 1, 2019, doi: 10.1186/s12874-019-0821-x.[44] J. M. Reps, M. Soledad Cepeda, and P. B. Ryan, “Wisdom of the Croud: Development and validation of a patient-level prediction model for opioid use disorder using population-level claims data,” PLoS One, vol. 15, no. 2, pp. 1–12, 2020, doi: 10.1371/journal.pone.0228632.[45] D. Molina and Á.-M. Miguel, “Estado de la investigación clínica en Colombia State of the clinical research in Colombia,” Acta Médica Colomb., vol. 43, no. 4, pp. 179–182, 2018.[46] R. Pérez Águila, J. L. Montes de Oca Montano, and A. Home Martínez, “Indización biomédica: sus tesauros, bases de datos y representación del contenido temático de la bibliografía especializada,” Bibl. Univ., vol. 26, no. 1, pp. 35–46, 2023, doi: 10.22201/dgbsdi.0187750xp.2023.1.1483.[47] Y. Kim et al., “Perioperative Serum 25-Hydroxyvitamin D Levels as a Predictor of Postoperative Opioid Use and Opioid Use Disorder: a Cohort Study,” J. Gen. Intern. Med., vol. 35, no. 9, pp. 2545–2552, 2020, doi: 10.1007/s11606-020-06001-y.[48] E. Kinnaird, A. Kimergård, S. Jennings, C. Drummond, and P. Deluca, “From pain treatment to opioid dependence: A qualitative study of the environmental influence on codeine use in UK adults,” BMJ Open, vol. 9, no. 4, pp. 1–10, 2019, doi: 10.1136/bmjopen-2018-025331.[49] C. Barbosa-Leiker, A. N. C. Campbell, R. K. McHugh, C. Guille, and S. F. Greenfield, “Opioid Use Disorder in Women and the Implications for Treatment,” Psychiatr. Res. Clin. Pract., vol. 3, no. 1, pp. 3–11, 2021, doi: 10.1176/appi.prcp.20190051.[50] S. A. Dominguez-Lara, “El odds ratio y su interpretación como magnitud del efecto en investigación,” Educ. Médica, vol. 19, no. 1, pp. 64–65, Jan. 2018, doi: 10.1016/j.edumed.2017.01.008.[51] J. D. Jones, S. Mogali, and S. D. Comer, “Polydrug abuse: A review of opioid and benzodiazepine combination use,” Drug Alcohol Depend., vol. 125, no. 1–2, pp. 8–18, 2012, doi: 10.1016/j.drugalcdep.2012.07.004.[52] M. Jani, B. B. Yimer, T. Sheppard, M. Lunt, and W. G. Dixon, “Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study,” PLoS Med., vol. 17, no. 10, pp. 1–16, 2020, doi: 10.1371/journal.pmed.1003270.[53] H. Samples, E. A. Stuart, and M. Olfson, “Opioid Use and Misuse and Suicidal Behaviors in a Nationally Representative Sample of US Adults,” Am. J. Epidemiol., vol. 188, no. 7, pp. 1245–1253, 2019, doi: 10.1093/aje/kwz061.[54] J. Lutz, R. T. Gross, and A. M. Vargovich, “Difficulties in emotion regulation and chronic pain-related disability and opioid misuse,” Addict. Behav., vol. 87, no. July, pp. 200–205, 2018, doi: 10.1016/j.addbeh.2018.07.018.[55] D. Reyes Chiquete, J. C. González Ortiz, A. Mohar Betancourt, and A. Meneses García, “Epidemiologíadel dolor por cáncer,” Rev. la Soc. Esp. del Dolor, vol. 18, no. 2, pp. 118–134, 2011.[56] K. Levytska et al., “Opioid and benzodiazepine use in gynecologic oncology patients,” Int. J. Gynecol. Cancer, vol. 33, no. 5, pp. 786–791, 2023, doi: 10.1136/ijgc-2022-003955.[57] N. Hernández-Beltrán, S. Forero-Nieto, and C. Moreno B, “Distal sensory peripheral neuropathy by the human immunodeficiency virus (HIV): pathophysiology,” Acta Neurológica Colomb., vol. 29, no. 2, pp. 103–108, 2013, [Online]. Available: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-87482013000200006&lng=en&nrm=iso&tlng=es.[58] V. J. Madden, R. Parker, and B. R. Goodin, “Chronic pain in people with HIV: A common comorbidity and threat to quality of life,” Pain Manag., vol. 10, no. 4, pp. 253–260, 2020, doi: 10.2217/pmt-2020-0004.[59] J. Colasanti et al., “Chronic Opioid Therapy in People Living with Human Immunodeficiency Virus: Patients’ Perspectives on Risks, Monitoring, and Guidelines,” Clin. Infect. Dis., vol. 68, no. 2, pp. 291–297, 2019, doi: 10.1093/cid/ciy452.[60] A. S. Ospina, D. M. Benjumea G, and P. Amariles M, “Problemas de proceso y resultado relacionados con los medicamentos: evolución histórica de sus definiciones,” Rev. Fac. Nac. Salud Pública, vol. 29, no. 3, pp. 329–340, 2011, [Online]. Available: http://www.scielo.org.co/pdf/rfnsp/v29n3/v29n3a14.pdf.[61] M. J. Krimphove* et al., “Pd58-03 Opioid Prescriptions After Robotic Vs. Open Urologic Procedures,” J. Urol., vol. 201, no. Supplement 4, p. 2019, 2019, doi: 10.1097/01.ju.0000557171.89602.04.[62] P. Sayal, B. T. Bateman, M. Menendez, M. Eikermann, and K. S. Ladha, “Opioid use disorders and the risk of postoperative pulmonary complications,” Anesth. Analg., vol. 127, no. 3, pp. 767–774, 2018, doi: 10.1213/ANE.0000000000003307.[63] N. Mendoza-Elias, M. Dunbar, Z. Ghogawala, and R. G. Whitmore, “Opioid Use, Risk Factors, and Outcome in Lumbar Fusion Surgery,” World Neurosurg., vol. 135, pp. e580–e587, 2020, doi: 10.1016/j.wneu.2019.12.073.[64] A. A. Anoushiravani et al., “Risk factors associated with persistent chronic opioid use following THA,” Eur. J. Orthop. Surg. Traumatol., vol. 30, no. 4, pp. 681–688, 2020, doi: 10.1007/s00590-019-02618-w.[65] M. K. Dalton et al., “Long-term prescription opioid use among US military service members injured in combat,” J. Trauma Acute Care Surg., vol. 91, no. 2, pp. S213–S220, 2021, doi: 10.1097/TA.0000000000003133.[66] L. Lundgren, M. Padyab, M. Sandlund, and D. McCarty, “Frequency and recency of non-medical opioid use and death due to overdose or suicide among individuals assessed for risky substance use: A national registry study in Sweden,” J. Subst. Abuse Treat., vol. 134, no. December 2020, p. 108567, 2022, doi: 10.1016/j.jsat.2021.108567.[67] E. L. Garland, M. Trostheim, M. Eikemo, G. Ernst, and S. Leknes, “Anhedonia in chronic pain and prescription opioid misuse,” Psychol. Med., vol. 50, no. 12, pp. 1977–1988, 2020, doi: 10.1017/S0033291719002010.[68] National Institutes and H. and an educational grant from E. Pharmaceuticals, “Screener and Opioid Assessment for Patients with Pain- Revised (SOAPP®-R),” pp. 1–4, 2015.[69] TUTFG, “Preguntas PICO: ¿Qué son y cómo se formulan?” https://tutfg.es/preguntas-pico/ (accessed Apr. 03, 2024).[70] V. Hernández, “Estudios epidemiológicos: tipos, diseño e interpretación,” Enferm. Inflamatoria Intest. al Día, vol. 16, no. 3, pp. 98–105, 2017, doi: 10.1016/j.eii.2017.03.001.[71] Elsevier, “Elsevier at a glance Because informed decisions lead to better outcomes,” 2022, [Online]. Available: https://www.elsevier.com/about/this-is-elsevier.[72] PubMed Central, “PMC User Guide - PMC,” 2023. https://www.ncbi.nlm.nih.gov/pmc/about/userguide/ (accessed Apr. 03, 2024).[73] Elsevier, “Scopus \| Abstract and citation database \| Elsevier,” Scopus: Comprehensive, multidisciplinary, trusted abstract and citation database, 2024. https://www.elsevier.com/products/scopus (accessed Apr. 03, 2024).[74] M. J. Ajejas Bazán, “Glosario de descriptores en Ciencias de la Salud procedentes del tesauro DeCS y MESH.,” Univ. Complut. Madrid, 2017.[75] NCBI, “Introduction to MeSH,” Medical Subject Headings, 2019. https://www.nlm.nih.gov/mesh/introduction.html (accessed Apr. 03, 2024).[76] B. V. em S. Bireme, “DeCS - Descriptores en ciencias de la salud,” 2008. https://decs.bvsalud.org/es/ (accessed Apr. 03, 2024).[77] C. Manterola, P. Astudillo, E. Arias, and N. Claros, “Revisiones sistemáticas de la literatura. Qué se debe saber acerca de ellas,” Cir. Esp., vol. 91, no. 3, pp. 149–155, 2013, doi: 10.1016/j.ciresp.2011.07.009.[78] J. M. Fernández, “Valoración clínica del paciente antes de iniciar el tratamiento con opioides : herramientas de ayuda .,” pp. 1–45.spaLICENSElicense.txtlicense.txttext/plain; charset=utf-82000https://repositorio.unbosque.edu.co/bitstreams/16ca20e6-59e5-41e7-be5b-9f57620e1857/download17cc15b951e7cc6b3728a574117320f9MD52Anexo 1 Acta de aprobacion.pdfapplication/pdf862769https://repositorio.unbosque.edu.co/bitstreams/0e88cb0d-d1e5-45e4-b034-e3b11e794a45/download3ca9a52a4c8b51a2fa450031d1489211MD511Carta de autorizacion.pdfapplication/pdf194143https://repositorio.unbosque.edu.co/bitstreams/b369a64d-670f-47ff-9a72-bcdd8f1079b3/downloade540e37387fb9f86b6af1d6f1f3125fcMD512CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8899https://repositorio.unbosque.edu.co/bitstreams/1bd5b7b4-c426-4e23-a3d6-ce20975524e3/download3b6ce8e9e36c89875e8cf39962fe8920MD53ORIGINALTrabajo de grado.pdfTrabajo de grado.pdfapplication/pdf1827404https://repositorio.unbosque.edu.co/bitstreams/6e0e9d8a-166f-4131-980f-c2906515cde5/download3d807bb18e90285d84bbfe46d257e8adMD55TEXTTrabajo de grado.pdf.txtTrabajo de grado.pdf.txtExtracted texttext/plain74954https://repositorio.unbosque.edu.co/bitstreams/0d8cb2de-b288-4ccd-a421-c7148da31faf/download5727c19fafcbe6b0ea907e6cd99c0caaMD59THUMBNAILTrabajo de grado.pdf.jpgTrabajo de grado.pdf.jpgGenerated Thumbnailimage/jpeg4132https://repositorio.unbosque.edu.co/bitstreams/4cb80a00-7464-48cf-ac02-6b6d88645e40/download640f51954e3eee21e860ae1470fcf953MD51020.500.12495/12121oai:repositorio.unbosque.edu.co:20.500.12495/121212024-07-04 09:20:11.095http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://repositorio.unbosque.edu.coRepositorio Institucional Universidad El Bosquebibliotecas@biteca.com

Revisión sistemática sobre la identificación de factores predictores de la adicción a opioides

Publicaciones similares